Pfizer Announces RSV Vaccine Candidate
Pfizer announced positive top-line data from the phase III clinical trial, MATISSE (MATernal Immunization Study for Safety and Efficacy), investigating its bivalent respiratory syncytial virus (RSV) prefusion vaccine candidate, RSVpreF or PF-06928316, when administered to pregnant participants to help protect their infants from RSV disease after birth. Learn more about the results of this study.
|
Study: Fluoxetine Safe for Pediatric Refractory Nocturnal Enuresis
Nocturnal enuresis is a major health problem affecting 15% of children aged older than 5 years. Even though an annual spontaneous resolution rate of 15% has been reported, 1% to 2% of teenagers aged older than 15 years and 2% to 6% of adults continue to deal with this issue. Learn more about a study exploring fluoxetine use in treating nocturnal enuresis in children.
|
